Page last updated: 2024-08-21

berbamine and imatinib mesylate

berbamine has been researched along with imatinib mesylate in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dong, Q; Gan, X; Lu, Q; Wu, D; Xu, R; Xu, X; Yu, XF; Yu, Y; Zhao, X1
Liang, Y; Wei, YL; Xu, L; Xu, XH; Zhao, XY1
Gu, Y; Ma, T; Qiu, X; Xie, J; Xu, R; Yu, Y; Zhang, L; Zhang, X1
Liang, Y; Wei, YL; Xu, L; Zhao, XY1
Huang, H; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Zhao, Y1
Chen, T; Fang, Y; Gan, X; Gan, Y; Gu, Y; Huang, L; Huang, W; Li, H; Lou, G; Meng, Z; Tang, J; Wang, K; Xu, G; Xu, R; Xu, X; Zhang, X; Zheng, S; Zhou, H1

Trials

1 trial(s) available for berbamine and imatinib mesylate

ArticleYear
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.
    International journal of hematology, 2011, Volume: 94, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Benzamides; Benzylisoquinolines; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Treatment Outcome; Young Adult

2011

Other Studies

5 other study(ies) available for berbamine and imatinib mesylate

ArticleYear
Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
    Leukemia research, 2006, Volume: 30, Issue:1

    Topics: Alkaloids; Apoptosis; Benzamides; Benzylisoquinolines; Bone Marrow Cells; Caspase 3; Caspases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2006
Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Benzamides; Benzylisoquinolines; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines

2009
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Piperazines; Pyrimidines

2009
The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Anatomical record (Hoboken, N.J. : 2007), 2009, Volume: 292, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; G1 Phase; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Indicators and Reagents; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; Survivin; Tetrazolium Salts

2009
CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
    Blood, 2012, Dec-06, Volume: 120, Issue:24

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzamides; Benzylisoquinolines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Models, Molecular; Mutation; Neoplastic Stem Cells; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012